D-0833-2020 Class I Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0833-2020 was initiated by Taro Pharmaceuticals U.S.A., Inc. on December 20, 2019 and is designated Class I. Reason for recall: Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate. The recall status is terminated (terminated February 23, 2024).

Recall Details

Product Type
Drugs
Report Date
February 19, 2020
Initiation Date
December 20, 2019
Termination Date
February 23, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity

Product Description

Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.

Reason for Recall

Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Distribution Pattern

Nationwide in the U.S. and Puerto Rico.

Code Information

Lot #: 331771, Exp. June 2021